John B. Henneman III Sells 4,564 Shares of SeaSpine Holdings Corp (SPNE) Stock
SeaSpine Holdings Corp (NASDAQ:SPNE) Director John B. Henneman III sold 4,564 shares of the stock in a transaction on Monday, August 27th. The shares were sold at an average price of $14.72, for a total value of $67,182.08. Following the completion of the transaction, the director now owns 60,144 shares in the company, valued at $885,319.68. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
NASDAQ:SPNE opened at $14.87 on Friday. SeaSpine Holdings Corp has a 12-month low of $8.76 and a 12-month high of $15.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.48 and a current ratio of 3.20. The firm has a market capitalization of $214.07 million, a PE ratio of -5.76 and a beta of 0.40.
SeaSpine (NASDAQ:SPNE) last posted its quarterly earnings results on Monday, July 30th. The medical equipment provider reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.02). SeaSpine had a negative return on equity of 27.65% and a negative net margin of 21.75%. The company had revenue of $36.41 million during the quarter, compared to the consensus estimate of $34.12 million. analysts forecast that SeaSpine Holdings Corp will post -1.95 EPS for the current fiscal year.
A number of research analysts have commented on SPNE shares. ValuEngine upgraded SeaSpine from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. HC Wainwright reiterated a “buy” rating on shares of SeaSpine in a research report on Monday, July 16th. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price objective on shares of SeaSpine in a research report on Monday, July 30th. Finally, Zacks Investment Research upgraded SeaSpine from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Thursday, May 3rd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. SeaSpine presently has an average rating of “Buy” and a consensus target price of $16.20.
SeaSpine Company Profile
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine.
Further Reading: Growth Stocks
Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.